What are Nicotinic receptor partial agonist drugs?

Nicotinic receptor partial agonist drugs are pharmacologic agents that share a common mechanism (typically targeting Alpha-4 beta-2 nicotinic acetylcholine receptor). 6 are currently marketed, with 1 more in clinical development.

What are the marketed Nicotinic receptor partial agonist drugs?

Marketed Nicotinic receptor partial agonist drugs include Varinecline (Chantix), Chantix, Varenicline (VAR), Varenicline (Champix), Varenicline Pill, Standard Duration Varenicline.

Nicotinic receptor partial agonist

6 marketed 1 in Phase 3

This page covers all Nicotinic receptor partial agonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Alpha-4 beta-2 nicotinic acetylcholine receptor, α4β2 neuronal nicotinic acetylcholine receptors, Nicotinic acetylcholine receptors (alpha4beta2 subtype).

Targets

Alpha-4 beta-2 nicotinic acetylcholine receptor · α4β2 neuronal nicotinic acetylcholine receptors · Nicotinic acetylcholine receptors (alpha4beta2 subtype)

Marketed (6)

Varinecline (Chantix) · American University of Beirut Medical Center · Psychiatry / Addiction Medicine
Varenicline is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor that reduces nicotine cravings and blocks the rewarding effects of smoking.
Chantix · Pfizer Inc. · Neuroscience
Varenicline binds α4β2 neuronal nicotinic acetylcholine receptors as partial agonist, blocking nicotine binding and dopamine reward.
Varenicline (VAR) · University of Oklahoma · Addiction/Smoking Cessation
Varenicline is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor that reduces nicotine cravings and blocks the rewarding effects of smoking.
Varenicline (Champix) · University of British Columbia · Addiction/Smoking Cessation
Varenicline is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor that reduces nicotine cravings and blocks the rewarding effects of smoking.
Varenicline Pill · National Institute on Drug Abuse (NIDA) · Addiction/Smoking Cessation
Varenicline is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor that reduces nicotine cravings and blocks the rewarding effects of nicotine.
Standard Duration Varenicline · University of Wisconsin, Madison · Addiction/Smoking Cessation
Varenicline is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor that reduces nicotine cravings and blocks the rewarding effects of nicotine.

Phase 3 pipeline (1)

Varenicline Tartarate · Pfizer · Addiction
Varenicline works by binding to nicotinic acetylcholine receptors in the brain, reducing the rewarding effects of smoking and alleviating withdrawal symptoms.